Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer

Journal of Clinical Oncology

Volumn 34, Issue 25, 2016, Pages 2980-2987

  Gettinger, Scott ^a   Rizvi, Naiyer A ^b   Chow, Laura Q ^c   Borghaei, Hossein ^d   Brahmer, Julie ^e   Ready, Neal ^f   Gerber, David E ^g   Shepherd, Frances A ^h   Antonia, Scott ^k   Goldman, Jonathan W ^i,l   Juergens, Rosalyn A ^k   Laurie, Scott A ^j   Nathan, Faith E ^l   Shen, Yun ^l   Harbison, Christopher T ^l   Hellmann, Matthew D ^b  

^a YALE CANCER CENTER   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d FOX CHASE CANCER CENTER   (United States)

^e JOHNS HOPKINS UNIVERSITY   (United States)

^f Medical Center   (United States)

^g UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^h PRINCESS MARGARET HOSPITAL   (Canada)

ⁱ MCMASTER UNIVERSITY   (Canada)

^j OTTAWA REGIONAL CANCER CENTRE   (Canada)

^k Cancer Center and Research Institute   (United States)

^l UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; AMYLASE; ANTINEOPLASTIC AGENT; ASPARTATE AMINOTRANSFERASE; ERLOTINIB; NIVOLUMAB; PROGRAMMED DEATH 1 LIGAND 1; PROTEIN TYROSINE KINASE INHIBITOR; TRIACYLGLYCEROL LIPASE; MONOCLONAL ANTIBODY;

ADJUVANT THERAPY; ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMYLASE BLOOD LEVEL; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; COHORT ANALYSIS; CONFERENCE PAPER; CONSTIPATION; DEHYDRATION; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HEART FAILURE; HUMAN; HYPERGLYCEMIA; HYPONATREMIA; HYPOTHYROIDISM; LUNG INFECTION; MAJOR CLINICAL STUDY; MALE; METASTASIS; MONOTHERAPY; NAUSEA; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PRURITUS; RASH; SYSTEMIC THERAPY; TREATMENT RESPONSE; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; VOMITING; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIAL; LUNG NEOPLASMS; MIDDLE AGED; PATHOLOGY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; COHORT STUDIES; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING;

EID: 84983652291     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2016.66.9929     Document Type: Conference Paper

References (33)

1. Kelly K, Crowley J, Bunn PA Jr, et al: Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: A Southwest Oncology Group trial. J Clin Oncol 19: 3210-3218, 2001
2. National Comprehensive Cancer Network: NSCLC Guidelines v7. http://www.nccn.org/ professionals/physician-gls/f-guidelines.asp#nscl
3. Sandler A, Gray R, Perry MC, et al: Paclitaxelcarboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542-2550, 2006
4. Scagliotti GV, De Marinis F, Rinaldi M, et al: Phase III randomized trial comparing three platinumbased doublets in advanced non-small-cell lung cancer. J Clin Oncol 20:4285-4291, 2002
5. Scagliotti GV, Parikh P, von Pawel J, et al: Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 26:3543-3551, 2008
6. Schiller JH, Harrington D, Belani CP, et al: Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346: 92-98, 2002
7. Patel JD, Socinski MA, Garon EB, et al: PointBreak: A randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer. J Clin Oncol 31:4349-4357, 2013
8. Haaland B, Tan PS, de Castro G, Jr., et al: Metaanalysis of first-line therapies in advanced non-smallcell lung cancer harboring EGFR-activating mutations. J Thorac Oncol 9:805-811, 2014
9. Kuykendall A, Chiappori A: Advanced EGFR mutation-positive non-small-cell lung cancer: Case report, literature review, and treatment recommendations. Cancer Contr 21:67-73, 2014
10. Rosell R, Carcereny E, Gervais R, et al: Erlotinib versus standard chemotherapy as firstline treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial. Lancet Oncol 13:239-246, 2012
11. Sequist LV, Yang JC, Yamamoto N, et al: Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 31: 3327-3334, 2013
12. SolomonBJ,MokT,KimDW,etal:First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med 371:2167-2177, 2014
13. Steuer CE, Khuri FR, Ramalingam SS: The next generation of epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of lung cancer. Cancer 121:E1-E6, 2015
14. Gettinger SN, Horn L, Gandhi L, et al: Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol 33: 2004-2012, 2015
15. Larkin J, Lao CD, Urba WJ, et al: Efficacy and safety of nivolumab in patients with BRAF V600 mutant and BRAF wild-type advanced melanoma: A pooled analysis of 4 clinical trials. JAMA Oncol 1: 433-440, 2015
16. Pardoll DM: The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12: 252-264, 2012
17. Schadendorf D, Hodi FS, Robert C, et al: Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol 33:1889-1894, 2015
18. Topalian SL, Sznol M, McDermott DF, et al: Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 32:1020-1030, 2014
19. Brahmer JR, Drake CG, Wollner I, et al: Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: Safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 28:3167-3175, 2010
20. Wang C, Thudium KB, Han M, et al: In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in nonhuman primates. Cancer Immunol Res 2:846-856, 2014
21. Brahmer J, Reckamp KL, Baas P, et al: Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 373: 123-135, 2015
22. Borghaei H, Paz-Ares L, Horn L, et al: Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373: 1627-1639, 2015
23. OPDIVO (nivolumab) [package insert]. Princeton, NJ, Bristol-Myers Squibb Company, October 2015
24. European public assessment report (EPAR) for nivolumab BMS product information: Summary of product characteristics. http://www.ema.europa.eu/docs/ en-GB/document-library/EPAR-Product-Information/ human/003985/WC500189765.pdf
25. Eisenhauer EA, Therasse P, Bogaerts J, et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 45:228-247, 2009
26. Goldstraw P (ed): International Association for the Study of Lung Cancer: Staging Manual in Thoracic Oncology. Orange Park, FL, Editorial Rx Press, 2009
27. National Cancer Institute: Common Terminology Criteria for Adverse Events v4.0. NIH publication 09-7473. May 29, 2009 (v.4.03: June 14, 2010). http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE-4.03-2010-06-14-QuickReference-8.5x11.pdf
28. Clopper CJ, Pearson ES: The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika 26:404-413, 1934
29. Greenwood M.: The natural duration of cancer. Reports on Public Health and Medical Subjects. 33:1-26. London, United Kingdom, HM Stationery Office, 1926
30. Rizvi NA, Mazières J, Planchard D, et al: Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (Check-Mate 063): A phase 2, single-arm trial. Lancet Oncol 16: 257-265, 2015
31. KEYTRUDA (pembrolizumab) [package insert]. Whitehouse Station, NJ, Merck Sharp & Dohme, a subsidiary of Merck, October 2015
32. Champiat S, Ferté C, Lebel-Binay S, et al: Exomics and immunogenics: Bridging mutational load and immune checkpoints efficacy. OncoImmunology 3:e27817, 2014
33. Rizvi NA, Hellmann MD, Snyder A, et al: Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348:124-128, 2015